Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Exploring the next generation of antibody–drug conjugates
Kyoji Tsuchikama, Yasuaki Anami, Summer Y. Y. Ha, et al.
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 3, pp. 203-223
Open Access | Times Cited: 172

Showing 26-50 of 172 citing articles:

Antibody-drug conjugates targeting SSEA-4 inhibits growth and migration of SSEA-4 positive breast cancer cells
Muhammad Usama, Yu-Chieh Hsu, Mahdieh Safaei, et al.
Cancer Letters (2025) Vol. 611, pp. 217453-217453
Closed Access
Antibody-Drug Conjugates in Breast Cancer: The Road Towards Biologically-Informed Selection and Sequencing
Tess A. O’Meara, Paolo Tarantino, Stefania Morganti, et al.
Current Oncology Reports (2025)
Closed Access
Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
Yangyang Gao, Yuwei Xia, Yixin Chen, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
The potential of antibody-drug conjugates for effective therapy in diffuse large B-cell lymphoma
Gulrayz Ahmed, Mehdi Hamadani, Taha Al‐Juhaishi
Expert Opinion on Biological Therapy (2025)
Closed Access
Mechanisms for resistance to BCMA-targeted immunotherapies in multiple myeloma
Tingting Yue, Yue Sun, Yun Dai, et al.
Blood Reviews (2025), pp. 101256-101256
Closed Access
LINC00870 promotes imatinib resistance in gastrointestinal stromal tumor via inhibiting PIGR glycosylation modifications
Yuan Li, Zhiqiang Dai, Zewei Cheng, et al.
Heliyon (2025) Vol. 11, Iss. 3, pp. e41934-e41934
Open Access
Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, et al.
Vaccines (2025) Vol. 13, Iss. 1, pp. 69-69
Open Access
Modular Synthesis of Anti-HER2 Dual-Drug Antibody-Drug Conjugates Demonstrating Improved Toxicity
Christine S. Nervig, M. S. Rice, Marcello Marelli, et al.
Bioconjugate Chemistry (2025)
Closed Access
Applications of cell penetrating peptide-based drug delivery system in immunotherapy
Jingjing Du, Ruyan Zhang, Shuqi Jiang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
AACDB: Antigen-Antibody Complex Database — a Comprehensive Database Unlocking Insights into Interaction Interface
Yuwei Zhou, Wenwen Liu, Ziru Huang, et al.
(2025)
Open Access
AACDB: Antigen-Antibody Complex Database — a Comprehensive Database Unlocking Insights into Interaction Interface
Yuwei Zhou, Wenwen Liu, Ziru Huang, et al.
(2025)
Open Access
Potential Theranostics of Breast Cancer with Copper-64/67 Sarcophagine-trastuzumab
Stacey E. Rudd, Jessica Van Zuylekom, Carleen Cullinane, et al.
Chemical Science (2025)
Open Access
Identifying Molecular Mechanisms of Cinnamomum cassia in the Treatment of Osteoporosis Based on Network Pharmacology and Validations
Xianwen Sun, Jun Fei
Pharmacognosy Magazine (2025)
Closed Access
Macromolecular Diamidobenzimidazole Conjugates Activate STING
Karan Arora, Taylor L. Sheehy, Jacob A. Schulman, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Closed Access
Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates
Young‐Ho Oh, Dao T. T. An, Jaebeom Park, et al.
Bioorganic & Medicinal Chemistry Letters (2025), pp. 130114-130114
Open Access
Diverse Roles of Antibodies in Antibody–Drug Conjugates
Aiko Yamaguchi, H. Charles Manning
Pharmaceuticals (2025) Vol. 18, Iss. 2, pp. 180-180
Open Access
Receptor-ligand interactions for optimized endocytosis in targeted therapies
Yejin Sung, Young‐Jin Choi, Eun Sun Kim, et al.
Journal of Controlled Release (2025) Vol. 380, pp. 524-538
Open Access
Glycoscience in Advancing PD-1/PD-L1-Axis-Targeted Tumor Immunotherapy
Qianqian Sun, Senlian Hong
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1238-1238
Open Access
An Affibody-Cytotoxin Conjugate-Based Nanoagent for EGFR Targeting and Precise Therapy of Epidermal Squamous Cell Carcinoma
Xiaoyuan Yang, Xuelin Xia, Qingrong Li, et al.
ACS Applied Nano Materials (2025)
Closed Access
A bioengineered antibody conjugate reshape dendritic cell viability for immune-tolerance modulation
Xiaohong Chen, Yalin Wang, Tao Xu, et al.
Chemical Engineering Journal (2025), pp. 160431-160431
Closed Access
Six events that shaped antibody approvals in oncology
Suman Paul, Shibin Zhou
Frontiers in Immunology (2025) Vol. 16
Open Access
Challenges and opportunities in single-domain antibody-based tumor immunotherapy
Xiaozhi Xi, Guo Shu-hua, Yuchao Gu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189284-189284
Closed Access
Pincer‐Type Pt(II)‐NHC Antibody‐Drug Conjugate for HER‐2‐Targeted Chemoimmunotherapy
Tao Huang, Wei-Ta Huang, G. M. Huang, et al.
Advanced Healthcare Materials (2025)
Open Access
Understanding the Toxicity Profile of Approved ADCs
P Martínez, Alfonso López de Sá, Cristina Díaz‐Tejeiro, et al.
Pharmaceutics (2025) Vol. 17, Iss. 2, pp. 258-258
Open Access
Cancer-targeting drug conjugates drives a new era in precise cancer treatment
Jia Deng, Jianbin Shi, Dan Li, et al.
Chinese Chemical Letters (2025), pp. 110960-110960
Closed Access

Scroll to top